Opus Genetics (IRD) Other Non-Current Liabilities (2010 - 2026)
Opus Genetics (IRD) reported Other Non-Current Liabilities of $77.3 million for Q1 2026, up 197.67% on a QoQ basis from $26.0 million in Q4 2025.
Opus Genetics (IRD) has 15 years of Other Non-Current Liabilities data on file, last reported at $77.3 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $77.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.3 million (changed N/A YoY) and the FY2025 annual result came in at $26.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $77.3 million in Q1 2026 per IRD's latest filing, from $26.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $77.3 million in Q1 2026 and bottomed at $74000.0 in Q4 2023.
- The 4-year median for Other Non-Current Liabilities is $1.2 million (2023), against an average of $16.7 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.35 Mn |
| Dec 31, 2025 | 25.99 Mn |
| Jun 30, 2025 | 11.80 Mn |
| Mar 31, 2024 | 99,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 93,000.00 |
| Jun 30, 2023 | 1.18 Mn |
| Dec 31, 2020 | 27.96 Mn |
| Sep 30, 2020 | 110,781.00 |
| Jun 30, 2020 | 268,811.00 |
| Mar 31, 2020 | 100,109.00 |
| Sep 30, 2019 | 123,872.00 |
| Jun 30, 2019 | 366,732.00 |
| Mar 31, 2019 | 794,215.00 |
| Dec 31, 2018 | 2.31 Mn |
| Sep 30, 2018 | 4.10 Mn |
| Jun 30, 2018 | 3.39 Mn |
| Mar 31, 2018 | 4.49 Mn |
| Dec 31, 2017 | 7.85 Mn |
| Sep 30, 2017 | 6.68 Mn |
| Jun 30, 2017 | 9.80 Mn |
| Mar 31, 2017 | 16.23 Mn |
| Dec 31, 2016 | 1.57 Mn |
| Sep 30, 2016 | 3.16 Mn |
| Jun 30, 2016 | 2.34 Mn |
| Mar 31, 2016 | 4.46 Mn |
| Dec 31, 2015 | 2.74 Mn |
| Sep 30, 2015 | 1.48 Mn |
| Jun 30, 2015 | 2.09 Mn |
| Mar 31, 2015 | 3.65 Mn |
| Dec 31, 2014 | 3.77 Mn |
| Sep 30, 2014 | 5.38 Mn |
| Jun 30, 2014 | 6.58 Mn |
| Mar 31, 2014 | 11.29 Mn |
| Dec 31, 2013 | 5.03 Mn |
| Sep 30, 2013 | 4.19 Mn |
| Jun 30, 2013 | 3.66 Mn |
| Mar 31, 2013 | 2.47 Mn |
| Dec 31, 2012 | 2.84 Mn |
| Sep 30, 2012 | 1.52 Mn |
| Jun 30, 2012 | 328,338.00 |
| Mar 31, 2012 | 1.13 Mn |
| Dec 31, 2011 | 868,725.00 |
| Sep 30, 2011 | 3.65 Mn |
| Jun 30, 2011 | 5.52 Mn |
| Dec 31, 2010 | 2.97 Mn |